Everything below concerns Pharmacokinetics. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
== Temperature instrumentation == Oil, gas and petrochemical processes are undertaken at specific temperatures. Measurement of temperature of fluids in the petrochemical industry is undertaken by temperature elements (TE). These can be Thermocouples or Platinum Resistance Temperature Detectors (RTDs). The latter are used for their good temperature response. Local temperature indicators (TI) are located on the inlet and outlet streams of heat exchangers to monitor the performance of the exchanger. In industrial applications gaseous or liquid fluids may be heated or cooled. This duty is undertaken in a heat exchanger, whereby the fluid is heated or cooled by heat transfer with a second fluid such as water, glycol, hot oil or another process fluid (the heating or cooling medium). Temperature control is used to maintain the desired temperature of the first fluid. A temperature sensor transmitter (TT) is located in the first fluid at its outlet from the heat exchanger. This measured temperature is fed to the temperature controller (TIC) where it is compared to the desired set point temperature. The output of the controller, which is related to the difference between the measured variable and the set point, is fed to a control valve (TCV) in the second fluid to adjust the flow of the heating or cooling medium. In the case of a fluid being cooled, if the temperature of the fluid rises the temperature controller acts to open the TCV increasing the flow of the cooling medium which increases the heat transfer and reduces the temperature of the first fluid.
Today, anti-U1 RNP antibodies are routinely included in autoimmune antibody panels used to evaluate patients with suspected connective tissue disease. Researchers continue to study these antibodies to understand their role in autoimmune disease.
== History and evaluation == Krebiozen was initially promoted by Stevan Durovic, a Yugoslavian physician who claimed that the substance was isolated from the blood serum of horses inoculated with Actinomyces bovis. Durovic claimed that Krebiozen had been useful in the treatment of cancer, mainly in cats and dogs. His claims were backed by Andrew Conway Ivy, a prominent physiologist, and by several politicians including Senator Paul Douglas (D-IL). Ivy became convinced that Krebiozen possessed anti-cancer properties, administered the substance to himself and colleagues, then to a dog, and eventually started testing Krebiozen on patients. Ivy called a press conference in 1951 at which he announced to an audience of journalists, politicians, doctors and potential investors that Krebiozen was a success. At the press conference, Ivy claimed that of 22 treated patients, 14 were alive and none had died of cancer. However, in reality 10 of the treated patients had died—all of cancer—at the time of the press conference. Shortly afterward, the Krebiozen Research Foundation was established by the Durovic brothers, with Ivy as president. Intrigued by Ivy's announcement, 10 hospitals and cancer research centers followed up on the trial and attempted to reproduce Ivy's claimed results. None of these independent researchers observed any effect of Krebiozen on cancer. A compilation of these institutions' negative data was reported in the Journal of the American Medical Association in 1951. Krebiozen's backers responded by alleging a conspiracy against the drug.
Sources: en.wikipedia.org
=== Other activities === High has been on NIH study sections for hematology and for therapeutic approaches to genetic disease. She was on the National Heart, Lung and Blood Advisory Council, on the NIH Clinical Center Advisory Council, and on the Board of Scientific Counsellors for the National Eye Institute. She did a four year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapy (2001–2005) and was the President of the American Society of Gene and Cell Therapy (2004–2005).
=== Pure element applications === Molybdenum powder is used as a fertilizer for some plants, such as cauliflower. Elemental molybdenum is used in NO, NO2, NOx analyzers in power plants for pollution controls. At 350 °C (662 °F), the element acts as a catalyst for NO2/NOx to form NO molecules for detection by infrared light. Molybdenum anodes replace tungsten in certain low voltage X-ray sources for specialized uses such as mammography. The radioactive isotope molybdenum-99 is used to generate technetium-99m, a short-lived daughter radionuclide (t½ ≃ 6.0 h) needed for medical imaging. The radioisotope is handled and stored as the molybdate (MoO2−4).
Golden Wings (From the beginning to 18:30) "Spiral Labyrinth" (Gaiden 2, episodes 1–14) "Silver-White Valley" (Gaiden 1, episodes 1–4) "The Mutineer" (Gaiden 2, ep. 15–18) "The Duelist" (Gaiden 2, ep. 19–22) Golden Wings (From 18:30 to the end) "The Retriever" (Gaiden 2, ep. 23–26) "Dream of the Morning, Song of Night" (Gaiden 1, ep. 5–8) "A Hundred Billion Stars, a Hundred Billion Lights" (Gaiden 1, ep. 13–24) "The Third Tiamat Battle" (Gaiden 2, ep. 27–28) My Conquest is the Sea of Stars Overture to a New War (From the beginning to 35:40) "Disgrace" (Gaiden 1, ep. 9–12) Overture to a New War (from 35:40 to the end) Main OVA series (The first two episodes have an expanded retelling in Overture to a New War)
Hematocrit measurements had previously been described in the literature, but Wintrobe's method differed in that it used a large tube that could be mass-produced to precise specifications, with a built-in scale. The fraction of red blood cells in the tube was measured after centrifugation to determine the hematocrit. The invention of a reproducible method for determining hematocrit values allowed Wintrobe to define the red blood cell indices.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.